WO2003085114A1 - Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell - Google Patents
Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell Download PDFInfo
- Publication number
- WO2003085114A1 WO2003085114A1 PCT/US2003/010384 US0310384W WO03085114A1 WO 2003085114 A1 WO2003085114 A1 WO 2003085114A1 US 0310384 W US0310384 W US 0310384W WO 03085114 A1 WO03085114 A1 WO 03085114A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- codons
- codon
- gene
- protein
- host cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention generally relates to genetic engineering and more particularly to methods for designing a synthetic gene de novo for the optimal expression of a known protein coding sequence in a host cell and further to increasing solubility and biological activity of the expressed protein.
- One of the primary goals of biotechnology is to provide large amounts of a desired protein by expressing a foreign gene in a host cell, for example E. coli .
- Significant advances have been made in pursuit of this goal, but the expression of some foreign genes in host cells remains problematic.
- Numerous factors are involved in determining the ultimate level and biological activity of a protein produced from expressing a foreign gene in a host cell . Among them are toxicity of the gene product and consequent instability of the foreign DNA sequence, level of RNA produced, improper or inefficient translation of the
- nucleotide sequences affect the expression levels of protein encoded by a foreign DNA sequence introduced into a cell. These include the promoter sequence, the structural coding sequence that encodes the desired foreign protein, 3' untranslated sequences, and polyadenylation sites. Because the structural coding region introduced into the cell is often the only "non-host" sequence introduced, it has been suggested that it could be a significant factor affecting the level of expression of the protein. This problem is created by the degeneracy of the genetic code and the fact that the various tRNA isoacceptors are not all used at the same frequencies by a single organism and the usage pattern varies from species to species as shown in Table 1.
- Plasmodium falciparum Homo sapiens http: //bioinformatics . weizmann. ac. il/databases
- codons at each position in an amino acid sequence may indeed reflect a purposeful evolutionary adaptation that defines temporal requirements for proper protein folding. Thus, incorrect protein folding is likely to occur when a heterologous gene is characterized by codon usage patterns that are disharmonious with the t-RNA abundances of the expression host.
- a strategy to overcome this problem is to make synthetic genes having codon usage patterns that are "harmonized ' ' to those of the expression host.
- the goal of codon harmonization is to deduce the relative rate of translation at each position in the foreign protein's sequence, based on the frequency with which its codon is used by that organism, and then match that rate to the rate anticipated for a synonymous codon in the host (E. coli ) that has a corresponding frequency of usage.
- a method for modifying a nucleotide sequence for enhanced accumulation and biological activity of its protein or polypeptide product in a host cell is provided.
- a method for the design of synthetic genes, de novo, for enhanced accumulation and biological activity of its encoded protein or polypeptide product in a host cell is provided.
- the present invention is drawn to a method for modifying structural coding sequence encoding a polypeptide to enhance accumulation of the polypeptide in a host cell, which comprises determining the amino acid sequence of the polypeptide encoded by the structural coding sequence and harmonizing codon frequency between the foreign DNA/RNA and the host cell DNA/RNA. This can be done by substituting codons in the foreign coding sequence with codons of similar frequency from the host DNA/RNA which code for the same amino acid. Therefore, the result would be the same amino acid sequence of the foreign gene encoded by host cell codons chosen on the basis of codon frequency.
- the present invention is further directed to synthetic structural coding sequences produced by the method of this invention where the synthetic coding sequence expresses its protein product in host cells at levels significantly higher than corresponding wild- type coding sequences.
- the present invention is also directed to a novel method for designing a synthetic gene for optimal expression of the encoded protein comprising determination of the frequency of usage of foreign gene codons and frequency of usage of host codons and substituting the foreign codons with a more-preferred host codon of similar frequency of usage, while maintaining a structural gene encoding the polypeptide, wherein these steps are performed sequentially and have a cumulative effect resulting in a nucleotide sequence containing a preferential utilization of the host cell codons for foreign codons for one or more of the amino acids present in the polypeptide.
- the present invention is also directed to a method which further includes a systematic bioinformatic analysis of secondary and tertiary structure of the protein sequence to be expressed that is carried out to correlate the utilization of infrequently-used codons with regions of protein structure (including but not limited to "turns" at the ends of coils, anti-parallel strands, extended beta sheets or helices and regions of disordered structure) that might necessarily require time to fold properly. Additional bioinformatic information such as protein sequence homology, motif homologies and secondary and/or tertiary structure homologies may be "overlaid” to refine the anticipated need for inclusion or exclusion of such codons.
- bioinformatic evaluation and design of nucleic acid sequence may be carried out to minimize formation of self-annealing hybrid ( "stem-loop ' ' ) structures in the resulting mRNA transcript that could affect translational rate, independent of frequency of codon usage.
- the present invention is further directed to host cells containing synthetic nucleic acid sequence (s), e.g. DNA or RNA, prepared by the methods of this invention and the expressed product of said synthetic sequence.
- synthetic nucleic acid sequence e.g. DNA or RNA
- FIG 1A, IB, 1C, IE and IE Example of spreadsheets from Excel program applied for harmonization of P. falciparum and E. coli .
- 1A FVO wild-type codons.
- IB proposed codons.
- 1C Codon Frequency Reference Values, Columns A-H.
- ID Codon Frequency Reference Values, Columns I-Q. IE) Harmonize.
- FIG 2. Soluble Expression of LSA-NRC from Tuner (DE3) containing plasmids pETKLSA-NRC/E or pETKLSA-NRC/H.
- Lanesl-4 pETK LSA-NRC/E containing an lsa-nrc/E gene whose codons were "optimized'' for E. coli expression by selection of the most common codon for each amino acid.
- Lanes 5-8 pETK LSA-NRC/H containing an lsa -nrc/H gene with codons "harmonized'' for E. coli expression by selection of codons that allowed the rate of translation to more closely match that predicted for genes being translated in P. falciparum.
- Lanes 1,2,5,6 are stained SDS-PAGE gels; Lanes 3,4,7,8 are Western blots of equivalent gels;
- FIG. 3 Coomassie blue stained SDS-PAGE for partially purified wild type MSP-142 (FVO) vs. single site pause mutant (FMP003) .
- FIG. 4 Coomassie stained SDA-PAGE on partially purified MSP-42 (FVO) (Wild-type vs. Single site pause mutant (FMP003) vs. Initiation Complex harmonized (FMP007) .
- FIG. 5A and 5B A) Coomassie blue stained SDS-PAGE (left panel) and Western blot analysis (right panel) of lysates from bacteria expressing FMP003, FMP007, or full gene harmonized. B) Solubility and partial purification of full gene harmonized MSP142 (FVO) in the presence (+Tween 80) and absence (-Tween 80) of Tween 80 detergent.
- Synthetic gene A nucleic acid which has been modified from its wild-type sequence.
- Host cell A cell into which a foreign gene is introduced.
- the host cell can be prokaryotic or eukaryotic .
- the present invention provides a method for modifying a nucleic acid sequence encoding a polypeptide to enhance expression and accumulation of the polypeptide in the host cell.
- the present invention provides novel synthetic nucleic acid sequences, encoding a polypeptide or protein that is foreign to a host cell, that is expressed at greater levels and with greater biological activity than in the host cell as compared to the wild-type sequence if expressed in the same host cell.
- the invention will primarily be described with respect to the preparation of synthetic DNA sequences (also referred to as nucleotide sequences, structural coding sequences or genes) which encode the P. falciparum genes, but it should be understood that the method of the present invention is applicable to any coding sequence encoding a protein foreign to a host cell in which the protein is expressed.
- DNA sequences modified by the method of the present invention are effectively expressed at a greater level in host cells than the corresponding non- modified DNA sequence.
- DNA sequences are modified to harmonize codon usage in the foreign gene with codon usage in the host cell by substituting synonymous codons from the host cell for foreign gene codons of- similar usage frequency, where necessary.
- codons that will be changed are those that are used more frequently in the host cell than in the foreign gene.
- Those foreign gene codons will be replaced with synonymous host cell codons that are used at the same frequency or less frequently.
- the decision to actually change a codon will depend on the location of the amino acid in the polypeptide.
- codons that are associated with intradomain segments will be replaced according to the paradigm described above. For codons associated with domains, it is probably sufficient to replace the codon only if the codon usage frequencies vary by +/- 50%. Depending on the degree of similarity of codon usage preferences in the foreign gene and the host cell, this could produce various results, ranging from no or little modification of the DNA sequence to many modifications.
- the former outcome would be expected for situations where the foreign gene and the expression host have relatively similar codon usage preferences or where bioinformatics focuses attention onto the coding sequences of the intradomain segments. The latter outcome would be expected for situations where the foreign gene and the expression hosts have extremely different codon usage preferences.
- the following description presents one process by which codon usage frequencies between genes can be compared.
- the present process was designed using a commercially available Excel program.
- Any program which supports a relational database which supports a set of operations defined by relational algebra can be used or designed. It generally includes tables composed of columns and rows for the data contained in the database. Each table has a primary key, being any column or set of columns the values of which uniquely identify the rows in the table.
- the relational database is subject to a set of operations (select, project, product, join, and divide) which form the basis of the relational algebra governing relations within the database. Relational databases are well known and documented (see, e.g., Nath, A. The Guide To SQL Server, 2 nd ed.
- amino acid sequence of the protein can be analyzed using commercially available computer software such as the "BackTranslate" program of the GCG Sequence Analysis Software Package, DNA Star, Vector NTI, or a simple "lookup table' 1 written in Excel, or a modification of a commercial package.
- a computer program product including a computer-usable medium having computer-readable program code embodied thereon relating to comparing codon frequencies and translation rate is envisioned.
- the computer program product includes computer-readable program code for providing, within a computing system, an interface for receiving a selection of one or more target gene sequence, determining codon frequencies of said target gene and comparing to frequencies of selected host gene sequence, determining whether or not a codon should be modified to match a host codon, and displaying the results of the determination.
- a text file is created that contains the entire wild type target gene sequence of the protein of interest, such that each codon is on a separate line separated by a hard return.
- This text file is imported into Excel simply by opening the file with Excel.
- Each codon of the sequence should occupy a single cell and all codons should be held in a single column of the spreadsheet .
- codons can be entired from the keyboard, one codon per cell all codons in a single column.
- a title for the sequence is inserted manually into the first row of the target sequence (See Figure 1A) .
- the name of the host (expression) species is selected from the dropdown box located in row 5 column D of the "Proposed Codons. 1 ' spreadsheet. This action finds that name in the range called “Host Species' 1 on the "Codon Frequency Reference Values' 1 spreadsheet, selects the number associated with that name and prints it to cell 119'' on that spreadsheet, where is it serves as an "index number.''.
- This index number is used in conjunction with the embedded Excel "vlookup 1 ' function to report Host Species codon usaged frequencies in column F of the "Codon Frequency Reference Values'' spreadsheet. The data in this column are also printed in Column D of the "Proposed Codons 1 ' spreadsheet. These data are reported for information only. They are not used further.
- the name of the target gene species is selected from the dropdown box located in row 5 column E of the "Proposed Codons .' ' spreadsheet. This action finds that name in the range called " " Gene Species 1 ' on the "Codon Frequency Reference Values'' spreadsheet, selects the number associated with that name and prints it to cell 119'' on that spreadsheet, where is it serves as another "index number. '' This second index number is used in conjunction with the embedded Excel "vlookup 11 function to report Gene Species codon usage frequencies in column G of the "Codon Frequency Reference Values'' spreadsheet. The data in this column are also printed in Column E of the "Proposed Codons' 1 spreadsheet.
- Two sets of unique names used to differentiate the various codons that can encode an amino acid by the usage frequency for that codon are created by using the embedded Excel "concatonate ' ' function to combine the amino acid name with the frequency of usage of the codon for that amino acid.
- the first set of names (Gene Species Code) is reported in the "Proposed Codons' 1 spreadsheet at Column F, and the second (Expression Host Code) is reported in the "Harmonize'' spreadsheet ( Figure ID) at Column B.
- Column J is for quality control.
- the cells in this column compare the amino acid residues predicted after harmonization (Column I, "proposed codon” spreadsheet) with those of the foreign sequence (Column B) . If “No” appears in any cell, the spreadsheet is corrupted and the calculation is not valid. If nothing is reported, the calculation is valid.
- Column K is for information. The cells in this column compare the codons predicted after harmonization (Column G, "proposed codon” spreadsheet) with those of the foreign sequence (Column C) and report “yes” if a change is proposed.
- Column L is another analysis tool, designed to identify "intradomain segments” or "pause regions” which should contain clusters of infrequently used codons.
- This tool examines the codon usage frequencies for the gene species by calculating a rolling average of the frequencies of usage of three consecutive codons found in Column E. Cell L5 sets the sensitivity of these calculations. Only average frequencies less than the "sensitivity value” are reported as "pause". The larger this sensitivity value, the more pause sites are shown.
- This information is the first application of bioinformatics, other applications such as secondary protein structure predictions and mRNA secondary structure predictions can also be supplied. Additionally protein class (Henaut and Danchin: Analysis and Predictions from Escherichia coli sequences in: Escherichia coli and Salmonella , Vol. 2, Ch. 114:2047-2066, 1996, Neidhardt FC ed. , ASM press, Washington, D.C.) and the changes in codon usage patterns associated with those classes will also represent additional important enhancements.
- an existing DNA sequence can be used as the starting material and modified by standard mutagenesis methods that are known to those skilled in the art or a synthetic DNA sequence having the desired codons can be produced by known oligonucleotide synthesis, PCR amplification, and DNA ligation methods.
- the frequency of codon usage in the wild-type DNA sequence is then compared to the frequency of codon usage in the host cell as shown in FIG. 1A-E.
- Those codons present in the wild-type DNA sequence that have high frequency are changed to the synonymous host codons that have high frequency and the codons present in the wild-type DNA sequence that have low frequency are changed to the synonymous host codons which have low frequencies. It is understood that any changes to the DNA sequence always preserve the amino acid sequence of the wild-type protein. It is also a goal, through using bioinformatic analysis of data in the public domain-so called data mining- to deduce a basis for preferential harmonization of certain codons.
- the invention is related to designing a fully "harmonized" synthetic gene.
- a systematic bioinformatic analysis of secondary structure of the protein sequence to be expressed is carried out to correlate the utilization of infrequently-used codons with regions of protein structure (including but not limited to "turns" at the ends of coils, anti-parallel strands, extended beta sheets or helices and regions of disordered structure) that might necessarily require time to fold properly. Additional bioinformatic information such as protein sequence homology and secondary and/or tertiary structure homology may be "overlaid” to refine the anticipated need for inclusion or exclusion of such codons.
- the aggregate may not be the best criterion to generate the rules by which codons are harmonized.
- Such criteria which probably can be established by protein sequence homology families, may be important. Those proteins which belong to different classes in other organisms/viruses may have preferred codon usages that are not simply those assumed from the aggregate sum of all codon usage in a particular organism.
- This type of bioinformatic information may add additional value by generating certain "rules" by which proteins have evolved and/or optimized their relative expression levels in specific biological contexts.
- rules may be employed in synthetic gene design and perhaps in development of altered paradigms for recombinant protein expression.
- the resulting DNA sequence prepared according to the above description is the preferred modified synthetic DNA sequence to be introduced into a host cell for enhanced expression and accumulation of the protein product in the cell.
- the method of the present invention has applicability to any DNA sequence that is desired to be introduced into a host cell to provide protein product.
- the preferred modified synthetic DNA sequences were constructed by PCR mutagenesis which required the use of numerous primers.
- the primers were designed to introduce the desired codon changes into the starting DNA sequence.
- the preferred size for the primers is around 40-70 bases, but larger and smaller primers have been utilized. In most situations, a minimum of 5 to 8 base pairs of homology to the template DNA are maintained to insure proper hybridization of the primer to the template. Multiple rounds of mutagenesis were sometimes required to introduce all of the desired changes and to correct any unintended sequence changes as commonly occurs in mutagenesis.
- a totally synthetic DNA encoding the target protein sequence was synthesized by using long oligonucleotides of 55-65 nt, each with overlapping complementary ends, that were extended and amplified using PCR to generate modules of the gene. These modules were assembled by using ligation of appropriate restriction nuclease sites that are present in the designed sequence to yield the final synthetic gene product. It is to be understood that extensive sequencing analysis using standard and routine methodology on both the intermediate and final DNA sequences is necessary to assure that the precise DNA sequence as desired is obtained.
- the DNA encoding the desired recombinant protein can be introduced into the cell in any suitable form including, the fragment alone, a linearized plasmid, a circular plasmid, a plasmid capable of replication, an episome, RNA, etc.
- the gene is contained in a plasmid.
- the plasmid is an expression vector.
- Individual expression vectors capable of expressing the genetic material can be produced using standard recombinant techniques. Please see e.g., Maniatis et al . , 1985 Molecular Cloning: A Laboratory Manual or DNA Cloning, Vol. I and II (D. N. Glover, ed. , 1985) for general cloning methods.
- MSP-1 42 fragment of FVO strain DNA was amplified by PCR from P. falciparum FVO genomic DNA by using the following primers:
- the primers contained restriction sites for restriction endonucleases, -Vcol and Notl , respectively.
- the digested D ⁇ A' s were purified by agarose gel extraction (QIAEXII, Qiagen, Chatsworth, CA) , ligated with T4 D ⁇ A ligase (Roche Biochemicals) and transformed into E.
- the initial approach to improve soluble protein expression was to apply the harmonization approach in a highly restricted way, which was to identify areas of the protein that were likely to represent intradomain segments owing to the presence of clusters of infrequently used codons in the wild type gene. This restricted approach was taken in order to minimize the cost of producing synthetic D ⁇ A.
- the analysis revealed a single codon within an intradomain segment near the ⁇ -terminus of the protein that might benefit from harmonization.
- pET (AT) FVO To prepare the expression vector, pET (AT) FVO.
- the 3' end of the wild type MSP1 42 (FVO) template was amplified by PCR with the sense internal primer EA3 and the anti-sense external primer, FVO- PCR2.
- the two PCR products were purified by gel extraction using QIAEX II, mixed (1:1) and were used as the template for a final amplification to produce full gene MSP-1 42 using flanking primers FVO-PCR1 and FVO- PCR2.
- the final clone was prepared by digesting the vector DNA, pET (AT) P-fMSP-l 2 (3D7), and insert DNA, with Ncol and Notl , and ligating together.
- the final pET(AT)FVO.A plasmid encodes 17 non-MSPl amino acids including a hexa-histidine tag at the ⁇ -terminus of P. falciparum FVO strain MSP-1 42 sequence. Construction of "Initiation complex" harmonized MSPl-42 expression vector pET(K)FVO.B
- the "initiation complex" harmonized MSPl-42 (FVO) clone was prepared by replacing the existing nucleotide sequence at the 5' -end of the MSPl-42 (FVO) gene sequence between restriction sites, Kpnl and BspMI with annealed oligonucleotides that were designed to "harmonize” codon usage between P. falciparum usage and the E . coli host.
- oligonucleotides pairs were synthesized, the sense strand, EA485-CDFVO,
- oligonucleotides were designed, as reverse complimentary strands with overhanging restriction sites at each end such that direct ligation into vector, pET (AT) FVO. A, would replace the existing 5' - nucleotide sequence between the Kpnl and BspMI sites.
- the oligonucleotides were annealed by adding lOOnmole/ml of each oligonucleotide, in a buffer containing 0.01 M Tris-HCl, pH 7.5, 0.1 M NaCl, and 0.001M EDTA. The mixture was heated to greater than 95°C for 10 minutes and then removed from the heat source and allowed to cool to room temperature.
- pET (AT) FVO To prepare the vector DNA, pET (AT) FVO. A, the vector was first restriction digested with BspMI such that the DNA was only restricted at the BspMI site located within the MSPl-42 (FVO) DNA and not at the second BspMI site, located in the vector DNA sequence.
- Linearized DNA 7.8kb, was separated by electrophoreses on agarose gels and then gel purified using QIAEX II. Extracted, purified linear BspMI pET(AT)FVO.A DNA was then digested with Kpnl to release the "foreign" sequence initiation complex, ⁇ 100bp.
- the vector DNA, containing Kpnl and BspMI restricted ends was gel purified and then ligated with the Kpnl and BspMI annealed oligonucleotides.
- the ligated DNA was transformed into E. coli host, BL21 DE3 and plated onto ampicillin plates. Colonies were screened for the correct insert by restriction digestion with Ncol.
- a series of PCR reactions yielded the four fragments.
- the first fragment begins with an Nde I site (before ATG codon) and ends with an Hinc II site.
- the second one starts with Hinc II and ends with a BsrG I site.
- the third one has BsrG I and Bst B I sites, and the last one had BstB I and Xho I sites (after the stop codon) .
- Each of the four fragments was generated separately and subcloned into a TA vector. In each instance, isolated transformants were selected and sequenced until a clone was identified as having the desired sequence and lacking mutations.
- Each of the fragments was then purified from an agarose gel and ligated into a TA cloning vector, in sequence, by using T4 DNA ligase.
- competent host cells TOP 10 supercompetent cells
- Isolated colonies of transformants were grown to prepare plasmid DNA for agarose gel electrophoresis analysis.
- Several plasmids that appeared to contain insert were sequenced completely in order to select a clone without mutation.
- Purified pCR 2.1-MSP (1-42) vector was digested with Nde I and Xho I and the insert purified on a 1% agarose gel.
- the purified 1.1 kbp fragment was ligated by using T4 DNA ligase into the pET(K) expression vector which had been digested with Nde I and Xho I and purified on 1% agarose gel.
- Competent host cells TOP 10 supercompetent cells
- Isolated colonies of transformant were grown to prepare plasmid DNA for agarose gel electrophoresis analysis.
- Several plasmids that appeared to contain the final insert were sequenced in order to verify the integrity of the restriction sites.
- E. coli B834 DE3 background cells were transformed with plasmids and were grown at 37°C to an OD 600 of 0.5-0.8.
- the culture temperature was reduced from 37°C to 25°C prior to induction of protein expression with 0. ImM IPTG. Induction was allowed to occur for 3.0 hours.
- cells were harvested by centrifugation at 27,666 x g for 1 hr at 4°C and the cell paste was stored at -80°C.
- Partial protein purification for comparison of expression levels. 2-3 g cells were suspended in 20 ml 10 mM sodium phosphate, 50 mM NaCl, 10 mM imidazole, pH 6.2. The sample was lysed by using a microfluidizer and Tween 80 was added to a final concentration of 1%, and NaCl to a final concentration of 500 mM. The sample was stirred for 15 mi a 0-4°C, centrifuged for 30 min at 27,000 g at 0-4°C and the supernate collected. The proteins were purified partially by chromatography on Ni +2 NTA Superflow (Qiagen, Chatsworth, CA) .
- a 700 ul column was equilibrated with 0.01M sodium chloride, pH 6.2, 500 mM sodium chloride, 0.01 M imidazole (Ni-buffer) and 0.5% Tween 80.
- the sample was applied and the column washed with 10 ml of 10 mM sodium phosphate, pH 6.2, 75 mM sodium chloride, 0.02 M imidazole.
- the pH was the changed by washing with 10 ml 10 mM sodium phosphate buffer, pH 8.0, 75 mM sodium chloride, 0.02 M imidazole.
- the proteins were eluted in 3.5 ml of 10 mM sodium phosphate, pH 8.0, 75 mM sodium chloride, 160 mM imidazole and 0.2% Tween 80.
- Cell paste was lysed in buffer containing phosphate buffered saline, pH 7.4 containing 0.01 M imidazole and 50U/ml benzonase. Following cell lyses by microfluidization, the lysate was either incubated in the presence or absence of the non-ionic detergent, Tween 80 (1.0%, v/v) on ice for 30 minutes with stirring, prior to centrifugation at 27,666 x g for 1 hr at 4°C. This clarified lysate was centrifuged at 100,000 g for 1 hour to show that the protein is expressed in soluble form in the cell cytoplasm or it was applied to a Ni +2 NTA superflow resin for partial purification.
- the non-ionic detergent Tween 80 (1.0%, v/v
- the mAbs used for evaluation of proper epitope structure included 2.2 (McBride et al , 1987, Mol . Biochem. Parasitol . , 23, 71-84; Hall et al , 1983, Mol . Biochem. Parasitol, 7, 247-65), 12.8 (McBride, 1987, supra; Blackman et al , 1990, J. Exp . Med., 172, 379-82), 7.5 (McBride, 1987, supra; Hall et al , 1983, supra), 12.10 (McBride, 1987, supra; Blackman et al , 1990, supra), 5.2 (Chang et al, 1988, Exp. Parasitol., 67, 1-11) .
- Example 4 Coomassie Blue stained SDS-PAGE & Western blot Analysis of lysates from bacteria expressing FMP003, FMP007, or full gene harmonized.
- E. coli codons were harmonized to P. falciparum codons with the objective of preserving all high and low codon usage rates throughout the gene sequence. This effort resulted in additional 10-fold increase in the yield of protein from the fully harmonized gene over that of FMP007 ( Figure 5A) and at least half of the protein was soluble in the host cell cytoplasm ( Figure 5B) .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002480504A CA2480504A1 (en) | 2002-04-01 | 2003-04-01 | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
| EP03726192A EP1490494A1 (en) | 2002-04-01 | 2003-04-01 | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
| AU2003228440A AU2003228440B2 (en) | 2002-04-01 | 2003-04-01 | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
| US10/677,641 US20040209323A1 (en) | 2002-11-12 | 2003-10-01 | Protein expression by codon harmonization and translational attenuation |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36974102P | 2002-04-01 | 2002-04-01 | |
| US60/369,741 | 2002-04-01 | ||
| US37968802P | 2002-05-09 | 2002-05-09 | |
| US60/379,688 | 2002-05-09 | ||
| US42571902P | 2002-11-12 | 2002-11-12 | |
| US60/425,719 | 2002-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003085114A1 true WO2003085114A1 (en) | 2003-10-16 |
Family
ID=28795006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2003/010384 Ceased WO2003085114A1 (en) | 2002-04-01 | 2003-04-01 | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20040005600A1 (en) |
| EP (1) | EP1490494A1 (en) |
| AU (1) | AU2003228440B2 (en) |
| CA (1) | CA2480504A1 (en) |
| WO (1) | WO2003085114A1 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006077258A1 (en) * | 2005-01-24 | 2006-07-27 | Dsm Ip Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
| WO2006066595A3 (en) * | 2004-12-22 | 2006-08-31 | Novozymes As | Recombinant production of serum albumin |
| WO2008000632A1 (en) * | 2006-06-29 | 2008-01-03 | Dsm Ip Assets B.V. | A method for achieving improved polypeptide expression |
| WO2007130606A3 (en) * | 2006-05-04 | 2008-01-31 | Univ California | Analyzing translational kinetics using graphical displays of translational kinetics values of codon pairs |
| WO2008027414A2 (en) | 2006-08-29 | 2008-03-06 | The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research | Novel p. falciparum vaccine proteins and coding sequences |
| WO2010036293A1 (en) * | 2008-09-24 | 2010-04-01 | The Johns Hokins University | Malaria vaccine |
| EP2062974A4 (en) * | 2006-08-21 | 2010-05-19 | Nat Univ Corp Kobe Univ | PROCESS FOR PRODUCING A FUSION PROTEIN |
| WO2013156443A1 (en) | 2012-04-17 | 2013-10-24 | F. Hoffmann-La Roche Ag | Method for the expression of polypeptides using modified nucleic acids |
| US20140087402A1 (en) * | 2010-10-05 | 2014-03-27 | Marker Gene Technologies, Inc. | Synthetic luciferase gene and protein |
| WO2017162461A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2020260431A1 (en) | 2019-06-28 | 2020-12-30 | F. Hoffmann-La Roche Ag | Method for the production of an antibody |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1594966B1 (en) | 2003-02-20 | 2008-10-22 | Athenix Corporation | Delta-endotoxin genes and methods for their use |
| CN101175850B (en) | 2005-04-08 | 2013-09-04 | 阿则耐克斯公司 | Identification of a new class of EPSP synthases |
| AR057205A1 (en) | 2005-12-01 | 2007-11-21 | Athenix Corp | GRG23 AND GRG51 GENES THAT CONFERENCE RESISTANCE TO HERBICIDES |
| US20080313769A9 (en) | 2006-01-12 | 2008-12-18 | Athenix Corporation | EPSP synthase domains conferring glyphosate resistance |
| EP1996009A4 (en) | 2006-03-02 | 2009-09-30 | Athenix Corp | Methods and compositions for improved enzyme activity in transgenic plant |
| US20100162433A1 (en) | 2006-10-27 | 2010-06-24 | Mclaren James | Plants with improved nitrogen utilization and stress tolerance |
| EP2728006B1 (en) | 2007-10-10 | 2017-11-22 | Athenix Corporation | Synthetic genes encoding CRY1AC |
| EP2334795B1 (en) | 2008-09-08 | 2014-04-30 | Athenix Corporation | Compositions and methods for expression of a heterologous nucleotide sequence in plants |
| CN101768213B (en) | 2008-12-30 | 2012-05-30 | 中国科学院遗传与发育生物学研究所 | A protein related to the number of plant tillers, its coding gene and application |
| CN101817879A (en) | 2009-02-26 | 2010-09-01 | 中国科学院遗传与发育生物学研究所 | Metallothionein and encoding gene and application thereof |
| DE102010056289A1 (en) | 2010-12-24 | 2012-06-28 | Geneart Ag | Process for the preparation of reading frame correct fragment libraries |
| WO2014043435A1 (en) | 2012-09-14 | 2014-03-20 | Bayer Cropscience Lp | Hppd variants and methods of use |
| JP6463724B2 (en) | 2013-03-15 | 2019-02-06 | バイエル クロップサイエンス エルピーBayer Cropscience Lp | Composition soybean promoter |
| AU2014332442B2 (en) | 2013-08-26 | 2019-12-19 | Biontech Research And Development, Inc. | Nucleic acids encoding human antibodies to Sialyl-Lewis |
| MX2016011745A (en) | 2014-03-11 | 2017-09-01 | Bayer Cropscience Lp | Hppd variants and methods of use. |
| US9856324B2 (en) | 2014-06-04 | 2018-01-02 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside GD2 |
| AR100874A1 (en) | 2014-06-16 | 2016-11-09 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | CHEMICAL GENES AND PROTEINS OF OXIDATIVE RESISTANCE, AND TRANSGENIC PLANTS THAT INCLUDE THE SAME |
| WO2016077123A1 (en) | 2014-11-10 | 2016-05-19 | Moderna Therapeutics, Inc. | Multiparametric nucleic acid optimization |
| US10724040B2 (en) | 2015-07-15 | 2020-07-28 | The Penn State Research Foundation | mRNA sequences to control co-translational folding of proteins |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
| JP7194594B2 (en) | 2016-05-18 | 2022-12-22 | モデルナティエックス インコーポレイテッド | Combinations of mRNAs encoding immunomodulatory polypeptides and uses thereof |
| US11001861B2 (en) | 2016-05-18 | 2021-05-11 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| WO2017201328A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE |
| SI3458083T1 (en) | 2016-05-18 | 2023-03-31 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
| EP3458104A1 (en) | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria |
| MA45036A (en) | 2016-05-18 | 2019-03-27 | Modernatx Inc | POLYNUCLEOTIDES CODING CITRINE FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 |
| WO2017201731A1 (en) | 2016-05-27 | 2017-11-30 | Beijing Vdjbio Co., Ltd. | Antibodies, composition and kits comprising same, and methods of use thereof |
| US11371056B2 (en) | 2017-03-07 | 2022-06-28 | BASF Agricultural Solutions Seed US LLC | HPPD variants and methods of use |
| US11180770B2 (en) | 2017-03-07 | 2021-11-23 | BASF Agricultural Solutions Seed US LLC | HPPD variants and methods of use |
| BR112019018056A2 (en) | 2017-03-07 | 2020-08-11 | BASF Agricultural Solutions Seed US LLC | recombinant nucleic acid molecule, expression cassette, host cell, plants, transgenic seeds, recombinant polypeptide, methods for checking tolerance and for controlling weeds, utility product and use of the nucleotide sequence |
| JP7285220B2 (en) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | Lipid nanoparticles comprising linked interleukin-12 (IL12) polypeptide-encoding polynucleotides |
| WO2019073069A1 (en) | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | Human antibodies to thomsen-nouvelle (tn) antigen |
| US20210032651A1 (en) | 2017-10-24 | 2021-02-04 | Basf Se | Improvement of herbicide tolerance to hppd inhibitors by down-regulation of putative 4-hydroxyphenylpyruvate reductases in soybean |
| WO2019083810A1 (en) | 2017-10-24 | 2019-05-02 | Basf Se | Improvement of herbicide tolerance to 4-hydroxyphenylpyruvate dioxygenase (hppd) inhibitors by down-regulation of hppd expression in soybean |
| WO2020088645A1 (en) | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
| CN118284624A (en) | 2021-11-19 | 2024-07-02 | 米罗生物有限公司 | PD-1 antibodies and their uses |
| IL315888A (en) | 2022-04-06 | 2024-11-01 | Mirobio Ltd | Engineered cd200r antibodies and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001068835A2 (en) * | 2000-03-13 | 2001-09-20 | Aptagen | Method for modifying a nucleic acid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082767A (en) * | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
| DE19640817A1 (en) * | 1996-10-02 | 1998-05-14 | Hermann Prof Dr Bujard | Recombinant manufacturing process for a complete malaria antigen gp190 / MSP 1 |
| EP1025244A2 (en) * | 1997-10-20 | 2000-08-09 | Genzyme Transgenics Corporation | NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS |
-
2003
- 2003-04-01 EP EP03726192A patent/EP1490494A1/en not_active Withdrawn
- 2003-04-01 WO PCT/US2003/010384 patent/WO2003085114A1/en not_active Ceased
- 2003-04-01 CA CA002480504A patent/CA2480504A1/en not_active Abandoned
- 2003-04-01 US US10/404,668 patent/US20040005600A1/en not_active Abandoned
- 2003-04-01 AU AU2003228440A patent/AU2003228440B2/en not_active Ceased
-
2007
- 2007-10-15 US US11/907,584 patent/US20080076161A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001068835A2 (en) * | 2000-03-13 | 2001-09-20 | Aptagen | Method for modifying a nucleic acid |
Non-Patent Citations (5)
| Title |
|---|
| KOMAR A A ET AL: "Synonymous codon substitutions affect ribosome traffic and protein folding during in vitro translation", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 462, no. 3, 3 December 1999 (1999-12-03), pages 387 - 391, XP004260651, ISSN: 0014-5793 * |
| MARTIN S L ET AL: "Total synthesis and expression in Escherichia coli of a gene encoding human tropoelastin", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 154, no. 2, 10 March 1995 (1995-03-10), pages 159 - 166, XP004042466, ISSN: 0378-1119 * |
| NAKAMURA Y ET AL: "CODON USAGE TABULATED FROM INTERNATIONAL DNA SEQUENCE DATABASES: STATUS FOR THE YEAR 2000", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 28, no. 1, January 2000 (2000-01-01), pages 292, XP002941557, ISSN: 0305-1048 * |
| PURVIS I J ET AL: "THE EFFICIENCY OF FOLDING OF SOME PROTEINS IS INCREASED BY CONTROLLED RATES OF TRANSLATION IN-VIVO A HYPOTHESIS", JOURNAL OF MOLECULAR BIOLOGY, vol. 193, no. 2, 20 January 1987 (1987-01-20), pages 413 - 418, XP000612033, ISSN: 0022-2836 * |
| THANARAJ T A ET AL: "Ribosome-mediated translational pause and protein domain organization.", PROTEIN SCIENCE, vol. 5, no. 8, August 1996 (1996-08-01), pages 1594 - 1612, XP009014613, ISSN: 0961-8368 * |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066595A3 (en) * | 2004-12-22 | 2006-08-31 | Novozymes As | Recombinant production of serum albumin |
| US7888489B2 (en) | 2005-01-24 | 2011-02-15 | Dsm Ip Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
| WO2006077258A1 (en) * | 2005-01-24 | 2006-07-27 | Dsm Ip Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
| CN101107354B (en) * | 2005-01-24 | 2012-05-30 | 帝斯曼知识产权资产管理有限公司 | Method for producing a compound of interest in a filamentous fungal cell |
| AU2006207463B2 (en) * | 2005-01-24 | 2011-03-17 | Dsm Ip Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
| EP2410048A1 (en) | 2005-01-24 | 2012-01-25 | DSM IP Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
| WO2007130606A3 (en) * | 2006-05-04 | 2008-01-31 | Univ California | Analyzing translational kinetics using graphical displays of translational kinetics values of codon pairs |
| WO2008000632A1 (en) * | 2006-06-29 | 2008-01-03 | Dsm Ip Assets B.V. | A method for achieving improved polypeptide expression |
| US8812247B2 (en) | 2006-06-29 | 2014-08-19 | Dsm Ip Assets B.V. | Method for achieving improved polypeptide expression |
| JP2009540845A (en) * | 2006-06-29 | 2009-11-26 | ディーエスエム アイピー アセッツ ビー.ブイ. | Methods for achieving improved polypeptide expression |
| EP2423315A1 (en) | 2006-06-29 | 2012-02-29 | DSM IP Assets B.V. | A method for achieving improved polypeptide expression |
| EA015925B1 (en) * | 2006-06-29 | 2011-12-30 | ДСМ АйПи АССЕТС Б.В. | A method for producing polypeptides |
| EP2062974A4 (en) * | 2006-08-21 | 2010-05-19 | Nat Univ Corp Kobe Univ | PROCESS FOR PRODUCING A FUSION PROTEIN |
| EP2066356A4 (en) * | 2006-08-29 | 2009-12-30 | Us Army | NEW P. FALCIPARUM VACCINE PROTEINS AND CODIER SEQUENCES |
| EP2505212A3 (en) * | 2006-08-29 | 2013-01-23 | The United States of America as Represented By the Secretary of the Army, Walter Reed Army Institute of Research | Novel P falciparum vaccine proteins and coding sequences |
| WO2008027414A2 (en) | 2006-08-29 | 2008-03-06 | The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research | Novel p. falciparum vaccine proteins and coding sequences |
| WO2010036293A1 (en) * | 2008-09-24 | 2010-04-01 | The Johns Hokins University | Malaria vaccine |
| US8501926B2 (en) | 2008-09-24 | 2013-08-06 | The Johns Hopkins University | Malaria vaccine |
| US20140087402A1 (en) * | 2010-10-05 | 2014-03-27 | Marker Gene Technologies, Inc. | Synthetic luciferase gene and protein |
| WO2013156443A1 (en) | 2012-04-17 | 2013-10-24 | F. Hoffmann-La Roche Ag | Method for the expression of polypeptides using modified nucleic acids |
| US12577293B2 (en) | 2012-04-17 | 2026-03-17 | Hoffmann-La Roche Inc. | Method for the expression of polypeptides using modified nucleic acids |
| WO2017162461A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| EP3964584A1 (en) | 2016-03-21 | 2022-03-09 | BioNTech SE | Trans-replicating rna |
| WO2020260431A1 (en) | 2019-06-28 | 2020-12-30 | F. Hoffmann-La Roche Ag | Method for the production of an antibody |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003228440A1 (en) | 2003-10-20 |
| US20040005600A1 (en) | 2004-01-08 |
| CA2480504A1 (en) | 2003-10-16 |
| EP1490494A1 (en) | 2004-12-29 |
| AU2003228440B2 (en) | 2008-10-02 |
| US20080076161A1 (en) | 2008-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003228440B2 (en) | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell | |
| DK2951309T3 (en) | INCREASED TRANSGEN EXPRESSION AND PROCESSING | |
| Faix et al. | Overexpression of the csA cell adhesion molecule under its own cAMP-regulated promoter impairs morphogenesis in Dictyostelium | |
| EP0482714A1 (en) | Increased production of thermus aquaticus DNA polymerase in E. coli | |
| US12410437B2 (en) | Incorporation of internal polya-encoded poly-lysine sequence tags and their variations for the tunable control of protein synthesis in bacterial and eukaryotic cells | |
| Folk et al. | A detailed mutational analysis of the eucaryotic tRNA1met gene promoter | |
| JPH0434559B2 (en) | ||
| CA2498776A1 (en) | Gene expression system based on codon translation efficiency | |
| Feiler et al. | Cloning of the pea cdc2 homologue by efficient immunological screening of PCR products | |
| WO2005000888A2 (en) | NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF | |
| Baillat et al. | CRISPR-Cas9 mediated genetic engineering for the purification of the endogenous integrator complex from mammalian cells | |
| CN115261363B (en) | Method for measuring RNA deaminase activity of APOBEC3A and RNA high-activity APOBEC3A variant | |
| US4820639A (en) | Process for enhancing translational efficiency of eukaryotic mRNA | |
| MXPA04005717A (en) | Expression system. | |
| López-Camarillo et al. | Entamoeba histolytica: comparative genomics of the pre-mRNA 3′ end processing machinery | |
| CN102439140A (en) | Chinese hamster ovary cell lines | |
| Dorai et al. | Investigation of Product Microheterogeneity | |
| NO852974L (en) | RECOMBINANT FACTOR VIII-R. | |
| CN115298204B (en) | ProNGF mutants and uses thereof | |
| KR100441201B1 (en) | Reporter gene-containing plasmid which is convertible to T-vector and the preparation method thereof | |
| WO2016145101A1 (en) | Methods of modulating nucleic acid stability and protein expression | |
| WO1996017933A2 (en) | Dna encoding a cell growth inhibiting factor and its product | |
| Weber et al. | Application of site-directed mutagenesis to RNA and DNA genomes | |
| WO2026060569A1 (en) | T7 rna polymerase mutant and application thereof | |
| KR20260025998A (en) | New regulatory elements for enhancing rna stability or mrna translation and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003228440 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2480504 Country of ref document: CA |
|
| REEP | Request for entry into the european phase |
Ref document number: 2003726192 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003726192 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003726192 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
